NATICK, Mass., January 14, 2025–Allurion Technologies, Inc. (“Allurion” or the “Company”) (NYSE: ALUR), a company dedicated to ending obesity, today announced that it has entered…
January 14, 2025
Oral DehydraTECH-tirzepatide evidenced reduced adverse events of 47% compared to injected Zepbound® Blood glucose reduction and insulin secretion levels from the oral DehydraTECH-tirzepatide were comparable…
January 14, 2025
Lexaria Bioscience First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
Lexaria Bioscience ( NASDAQ:LEXX ) First Quarter 2025 Results Key Financial Results Net loss: US$2.70m (loss widened by…
We recently compiled a list of the Why These 24 Stocks Are Skyrocketing. In this article, we are going to take a look at where…
January 13, 2025
Is Soleno Therapeutics (SLNO) the Top Small Cap Stock to Buy with the Highest Upside Potential?
We recently published a list of the Top 10 Small Cap Stocks to Buy with the Highest Upside Potential. In this article, we are going…
January 13, 2025
ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys
Transactions Continue to Progress and Remain on TrackIRVINE, Calif. and CAMBRIDGE, Mass., Jan. 13, 2025 (GLOBE NEWSWIRE) — ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier…
January 13, 2025
Skye Bioscience Provides 2025 Look Ahead and Year in Review
Expected Phase 2 obesity data in Q2 2025 and Q4 2025 will shape clinical potential and development path of distinctive CB1 inhibitorSAN DIEGO, Jan. 13,…
Company also announces strong enrollment progress for REMAIN-1 weight maintenance pivotal study High demand from patients and physicians indicates significant interest in REMAIN-1 study and…
— Preliminary unaudited net revenues from global sales of IMCIVREE® (setmelanotide) of approximately $42 million for the fourth quarter of 2024 and approximately $130 million…
January 09, 2025
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts.
Biotech stocks are poised for an exciting 2025 as experts watch for new weight-loss drugs, AI’s impact and Trump’s second presidency.
Scheduled for 13 weeks, the trial will assess the therapy’s safety, tolerability, and efficacy in weight loss.
The initiation of the phase 2 study is based on early-stage data, which show that patients who received VKTX’s obesity pill lost up to 8.2%…